BioCryst Pharmaceuticals (NASDAQ:BCRX) Issues Quarterly Earnings Results, Beats Estimates By $0.05 EPS

BioCryst Pharmaceuticals (NASDAQ:BCRX) announced its quarterly earnings data on Wednesday. The biotechnology company reported $0.14 EPS for the quarter, topping analysts’ consensus estimates of $0.09 by $0.05, Zacks reports. BioCryst Pharmaceuticals had a negative return on equity of 86.89% and a negative net margin of 40.90%. The firm had revenue of $180.29 million during the quarter, compared to analyst estimates of $165.67 million. During the same period last year, the company earned $0.06 earnings per share. The company’s revenue was up 13.1% on a year-over-year basis.

Here are the key takeaways from BioCryst Pharmaceuticals’ conference call:

• ORLADEYO revenue was $174.8 million, up 20% year over year excluding Europe, but included an upper-teens-million-dollar, one-time contribution from CareMed’s inventory build. BioCryst kept its full-year ORLADEYO guidance at $625 million–$645 million, saying future revenue should more closely reflect patient demand.
• BioCryst reported non-GAAP operating profit of $86 million, up 70% year over year, and non-GAAP net income of $71 million, more than doubling. It raised total 2026 revenue guidance to $715 million–$730 million, tightened operating expense guidance to $415 million–$425 million, and expects restructuring actions to generate $30 million–$35 million in annualized savings.
• Management described ORLADEYO prescriptions and net patient additions as strong, with early pediatric demand ahead of expectations and potential to exceed the previously estimated 500-patient opportunity. The company also launched pediatric pellets and plans to offer a newly approved 150 mg pellet formulation for patients 12 and older.
• The navenibart pivotal trial is fully enrolled, with 12-month top-line data expected in the third quarter of 2027; BioCryst is also preparing its BLA and launch plans. The company expects early BCX17725 data in Netherton syndrome by year-end and is evaluating early-stage external opportunities, but said further investment and development decisions will depend on the data and scientific assessment.

BioCryst Pharmaceuticals Trading Up 0.8%

Shares of NASDAQ:BCRX traded up $0.07 during mid-day trading on Wednesday, reaching $8.63. The stock had a trading volume of 1,931,364 shares, compared to its average volume of 4,885,920. The firm has a market cap of $2.21 billion, a PE ratio of -5.76 and a beta of 0.55. The firm has a 50 day simple moving average of $8.58 and a two-hundred day simple moving average of $8.74. BioCryst Pharmaceuticals has a twelve month low of $6.23 and a twelve month high of $11.22.

Key Headlines Impacting BioCryst Pharmaceuticals

Here are the key news stories impacting BioCryst Pharmaceuticals this week:

• Positive Sentiment: BioCryst earned $0.14 per share, topping the $0.09 consensus estimate and improving on $0.06 a year earlier. Revenue was $180.29 million, above the $165.67 million estimate and up 13.1% year over year. The company also raised its guidance. BioCryst Q3 earnings and raised guidance BioCryst third-quarter financial results
• Negative Sentiment: Despite the quarterly earnings beat, BioCryst continues to report a negative net margin and negative return on equity, indicating that profitability remains a concern. BioCryst earnings report

Analyst Ratings Changes

Several equities research analysts have recently commented on BCRX shares. Weiss Ratings cut shares of BioCryst Pharmaceuticals from a “hold (c)” rating to a “sell (d-)” rating in a research report on Tuesday, September 22nd. Wedbush lowered their target price on shares of BioCryst Pharmaceuticals from $21.00 to $20.00 and set an “outperform” rating for the company in a report on Thursday, August 6th. JPMorgan Chase & Co. upped their target price on shares of BioCryst Pharmaceuticals from $12.00 to $13.00 and gave the company a “neutral” rating in a research report on Wednesday, September 30th. Royal Bank Of Canada downgraded BioCryst Pharmaceuticals from an “outperform” rating to a “sector perform” rating and cut their price target for the company from $13.00 to $11.00 in a research note on Thursday, September 10th. Finally, Wall Street Zen upgraded BioCryst Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research report on Saturday, October 24th. Six equities research analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has given a Sell rating to the company. According to MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average price target of $20.75.

About BioCryst Pharmaceuticals

BioCryst Pharmaceuticals, Inc is a biotechnology company focused on developing and commercializing oral medicines for rare and serious diseases. The company uses structure-based drug design and small-molecule research to develop therapies intended to address conditions with limited treatment options.

BioCryst’s primary commercial product is Orladeyo (berotralstat), an oral medication used to prevent hereditary angioedema attacks in adults and pediatric patients aged 12 and older. The company also maintains a pipeline of investigational therapies for complement-mediated diseases and other rare disorders, including programs designed to inhibit components of the complement system.

Founded in 1986 and headquartered in Durham, North Carolina, BioCryst has historically conducted research and commercial activities in the United States and worked with international partners to make its products available in additional markets.